These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. [L-dopa and amphetamine treatment of acinetic Parkinsonism patients with and without stereotaxic surgery]. Umbach W Beitr Neurochir; 1966; 13():45-51. PubMed ID: 5341079 [No Abstract] [Full Text] [Related]
49. [Clinical experimentation of DOPA in Parkinsonian syndromes]. Pazzagli A; Amaducci L Riv Neurobiol; 1966; 12(1):138-45. PubMed ID: 5959306 [No Abstract] [Full Text] [Related]
50. [Our experience with the treatment of the parkinsonian syndrome with L-dopa. II. Instrumental evaluation of the kinetic changes]. Bergamini L; Bonzanino O; Brignolio F; Fabiani A; Fariello R; Mombelli AM; Mutani R; Pisani W; Postir A; Quattroccolo G; Riccio A; Sabbatini F; Sandigliano G; Schiffer D Riv Patol Nerv Ment; 1969 Dec; 90(6):471-80. PubMed ID: 5406112 [No Abstract] [Full Text] [Related]
51. [Modalities of treatment of Parkinsonian syndrome with L-dopa]. Yanniotis G; Eisenring JJ; Gauthier G; Tissot R; de Ajuriaguerra J Int J Neurol; 1972; 9(1):23-32. PubMed ID: 5086635 [No Abstract] [Full Text] [Related]
52. [Therapeutic association of amantadine and L-Dopa in parkinsonism]. Signorelli CD; D'Andrea F; De Divitiis E; Cerillo A Minerva Med; 1971 Oct; 62(82):4015-6. PubMed ID: 5125068 [No Abstract] [Full Text] [Related]
53. [Pathochemical bases for the treatment of parkinsonism]. Petelin LS; Tret'iakova KA; Pigarev VA; Romenskaia LK Zh Nevropatol Psikhiatr Im S S Korsakova; 1971 Dec; 71(12):1765-70. PubMed ID: 5143959 [No Abstract] [Full Text] [Related]
54. [Conservative therapy in the Parkinson syndrome]. Birkmayer W Wien Med Wochenschr; 1971 Nov; 121(46):827-9. PubMed ID: 5138823 [No Abstract] [Full Text] [Related]
55. [Will L-dopa replace surgery in parkinsonism?]. Vladyka V Cesk Neurol; 1973 Nov; 36(6):337-41. PubMed ID: 4755308 [No Abstract] [Full Text] [Related]
56. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements]. Kaufmann W; Butz P; Wiesendanger M Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871 [No Abstract] [Full Text] [Related]
57. [The therapeutic association of L-dopa and amantadine. Preliminary results in a group of patients with Parkinson's disease]. Gomirato G; Perfetti C Riv Neurobiol; 1970; 16(3):247-54. PubMed ID: 5518838 [No Abstract] [Full Text] [Related]
58. [L-dopa as a substitution for surgery in Parkinsonism?]. Vladyka V Cesk Neurol Neurochir; 1973 Nov; 36(6):337-41. PubMed ID: 4769636 [No Abstract] [Full Text] [Related]
59. [Treatment of Parkinson's syndrome with L-dopa. In operated and nonoperated cases]. Pimenta Ada M; Friguglietti DJ Rev Bras Med; 1971 Sep; 28(9):481-96. PubMed ID: 5139650 [No Abstract] [Full Text] [Related]
60. [Streoenchephalotomy in parkinsonism: late result of pneumotaxic method]. Matsumoto K; Oomoto T; Nanba S; Miyamoto T Geka Chiryo; 1971 Mar; 24(3):245-52. PubMed ID: 4927618 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]